Latest Health News

MedAdvisor Solutions reported a 16.6% revenue decline in 4Q FY25, driven by US market challenges, while completing the sale of its ANZ business and initiating a strategic review of its US operations.

MedAdvisor reports a significant revenue decline in FY25 amid US program delays but strengthens its balance sheet through a capital raise and ANZ business sale. The company signals a strategic pivot with potential US business divestment on the horizon.

EVE Health Group has completed its acquisition of Nextract, raised $1 million to fund manufacturing, and achieved key regulatory and commercial milestones for its pharmaceutical products targeting erectile dysfunction and dysmenorrhea.

Decidr AI Industries reported an 82% revenue jump in its AI platform during Q4 FY25, launched AI Mentors with The Growth Faculty, and divested its 13Seeds business to sharpen focus on AI innovation.

Micro-X has landed a significant supply agreement with a top US healthcare provider for its Rover Plus mobile X-ray units, while progressing clinical trials and development milestones for its innovative CT imaging products.

Doctor Care Anywhere has reported a landmark positive operating and investing cash inflow in Q2 2025, alongside modest consultation growth and strategic service expansion. The company reiterates its ambitious revenue and profitability targets amid ongoing cost transformation.

Osteopore Limited has posted a record AUD 835K revenue in Q2 CY25, driven by strong APAC sales and new European market access following EU MDR clearance. The company also advances clinical trials and refreshes key distribution channels.

TrivarX has secured key approvals and begun recruiting for its innovative mental health screening trial in US veterans, while also launching a wearable tech pilot with a Major League Baseball academy in the Dominican Republic.

Rhythm Biosciences has successfully validated its ColoSTAT® colorectal cancer test, secured its first strategic partnership for Genetype, and secured $1 million in non-dilutive funding, setting the stage for a transformative FY26.

Neurotech International reports encouraging Phase I human pharmacokinetic results for its pediatric cannabinoid drug NTI164, alongside published clinical trial data in Rett Syndrome and key regulatory progress in the US and Australia.

FlexiRoam Limited has achieved profitability in Q4 FY25, marking a significant turnaround with a positive EBITDA and net profit. Founder Jefrey Ong is appointed permanent CEO to steer the company’s next growth phase.

Vection Technologies capped FY25 with its highest monthly order intake ever, driven by defence and AI/XR contracts, while posting positive pro-forma cash flow despite payment timing issues.